UBS O'Connor’s Vera Therapeutics VERA Stock Holding History

UBS O'Connor’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,000	Closed	-$58.5K	–	611
2024 Q2	$58.5K	Buy	30,000 +10,000	+50%	+$397K	﹤0.01%	444
2024 Q1	$83K	Buy	+20,000	New	+$713K	﹤0.01%	429

Other funds holding VERA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS O'Connor's VERA Position: Q3 2025 in Review

UBS O'Connor sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 27,400 shares — an estimated $646K sold.

UBS O'Connor first reported a position in VERA in Q1 2023 and held it in 10 quarters. The position peaked at $2.44M in Q3 2023. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

UBS O'Connor reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 27,400 Vera Therapeutics shares in Q3 2025, an estimated $646K.
UBS O'Connor first reported a position in Vera Therapeutics in Q1 2023 and held it in 10 quarters.
UBS O'Connor's Vera Therapeutics position peaked at $2.44M in Q3 2023.
175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.